These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 9683846)
1. Amifostine: a radioprotector in locally advanced head and neck tumors. Wagner W; Prott FJ; Schonekas KG Oncol Rep; 1998; 5(5):1255-7. PubMed ID: 9683846 [TBL] [Abstract][Full Text] [Related]
2. Amifostine--a radioprotector in locally advanced head and neck tumors. Schönekäs KG; Wagner W; Prott FJ Strahlenther Onkol; 1999 Nov; 175 Suppl 4():27-9. PubMed ID: 10584137 [TBL] [Abstract][Full Text] [Related]
3. A new administration schedule for amifostine as a radioprotector in cancer therapy. Wagner W; Radmard A; Schönekaes KG Anticancer Res; 1999; 19(3B):2281-3. PubMed ID: 10472344 [TBL] [Abstract][Full Text] [Related]
4. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Bennett CL; Lane D; Stinson T; Glatzel M; Buntzel J Cancer Invest; 2001; 19(2):107-13. PubMed ID: 11296615 [TBL] [Abstract][Full Text] [Related]
5. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection? Vacha P; Fehlauer F; Mahlmann B; Marx M; Hinke A; Sommer K; Richter E; Feyerabend T Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464 [TBL] [Abstract][Full Text] [Related]
6. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Brizel DM; Wasserman TH; Henke M; Strnad V; Rudat V; Monnier A; Eschwege F; Zhang J; Russell L; Oster W; Sauer R J Clin Oncol; 2000 Oct; 18(19):3339-45. PubMed ID: 11013273 [TBL] [Abstract][Full Text] [Related]
7. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Büntzel J; Glatzel M; Kuttner K; Weinaug R; Fröhlich D Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):4-13. PubMed ID: 11917277 [TBL] [Abstract][Full Text] [Related]
8. A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. Bourhis J; De Crevoisier R; Abdulkarim B; Deutsch E; Lusinchi A; Luboinski B; Wibault P; Eschwege F Int J Radiat Oncol Biol Phys; 2000 Mar; 46(5):1105-8. PubMed ID: 10725619 [TBL] [Abstract][Full Text] [Related]
9. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Antonadou D; Pepelassi M; Synodinou M; Puglisi M; Throuvalas N Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):739-47. PubMed ID: 11849797 [TBL] [Abstract][Full Text] [Related]
10. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors]. Altmann S; Hoffmanns H Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138 [TBL] [Abstract][Full Text] [Related]
11. [Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial]. Vacha P; Marx M; Engel A; Richter E; Feyerabend T Strahlenther Onkol; 1999 Nov; 175 Suppl 4():18-22. PubMed ID: 10584135 [TBL] [Abstract][Full Text] [Related]
12. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer. Machtay M; Rosenthal DI; Chalian AA; Lustig R; Hershock D; Miller L; Weinstein GS; Weber RS Int J Radiat Oncol Biol Phys; 2004 May; 59(1):72-7. PubMed ID: 15093901 [TBL] [Abstract][Full Text] [Related]
13. Randomized double-blind trial of amifostine versus placebo for radiation-induced xerostomia in patients with head and neck cancer. Lee MG; Freeman AR; Roos DE; Milner AD; Borg MF J Med Imaging Radiat Oncol; 2019 Feb; 63(1):142-150. PubMed ID: 30461207 [TBL] [Abstract][Full Text] [Related]
14. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy. Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870 [TBL] [Abstract][Full Text] [Related]
15. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing. Rosenthal DI; Chambers MS; Weber RS; Eisbruch A Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519 [TBL] [Abstract][Full Text] [Related]
16. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer. Thorstad WL; Chao KS; Haughey B Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516 [TBL] [Abstract][Full Text] [Related]
17. Oral candidiasis in head and neck cancer patients receiving radiotherapy with amifostine cytoprotection. Nicolatou-Galitis O; Sotiropoulou-Lontou A; Velegraki A; Pissakas G; Kolitsi G; Kyprianou K; Kouloulias V; Papanikolaou I; Yiotakis I; Dardoufas K Oral Oncol; 2003 Jun; 39(4):397-401. PubMed ID: 12676261 [TBL] [Abstract][Full Text] [Related]
18. Amifostine reduces radiation therapy-induced dry mouth in head and neck cancer patients. Oncology (Williston Park); 2004 Sep; 18(10):1314, 1316. PubMed ID: 15526835 [No Abstract] [Full Text] [Related]
19. [Cytoprotection with amifostine in the framework of radiochemotherapy in previously irradiated head and neck carcinoma]. Büntzel J; Glatzel M; Schuth J; Weinaug R; Küttner K; Fröhlich D Strahlenther Onkol; 1999 Nov; 175 Suppl 4():37-40. PubMed ID: 10584140 [TBL] [Abstract][Full Text] [Related]
20. Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Büntzel J; Schuth J; Küttner K; Glatzel M Support Care Cancer; 1998 Mar; 6(2):155-60. PubMed ID: 9540175 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]